Platycodin D3CAS# 67884-03-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 67884-03-1 | SDF | Download SDF |
| PubChem ID | 70698293 | Appearance | Powder |
| Formula | C63H102O33 | M.Wt | 1387.47 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(2S,3R,4S,5S)-3-[(2S,3R,4S,5R,6S)-5-[(2S,3R,4S,5R)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4aR,5R,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-5,11-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate | ||
| SMILES | CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C(C5(CC4O)C)(CCC7C6(CC(C(C7(CO)CO)OC8C(C(C(C(O8)COC9C(C(C(C(O9)CO)O)O)O)O)O)O)O)C)C)(C)C)O)O)O)O)OC1C(C(C(CO1)O)OC1C(C(CO1)(CO)O)O)O | ||
| Standard InChIKey | XHKCYIRZWRRXNG-COMVGSAYSA-N | ||
| Standard InChI | InChI=1S/C63H102O33/c1-24-45(92-51-44(81)46(29(70)18-85-51)93-55-48(82)62(84,22-67)23-88-55)40(77)43(80)52(89-24)94-47-35(72)28(69)17-86-54(47)96-56(83)63-12-11-57(2,3)13-26(63)25-7-8-32-58(4)14-27(68)49(61(20-65,21-66)33(58)9-10-59(32,5)60(25,6)15-34(63)71)95-53-42(79)39(76)37(74)31(91-53)19-87-50-41(78)38(75)36(73)30(16-64)90-50/h7,24,26-55,64-82,84H,8-23H2,1-6H3/t24-,26-,27-,28-,29+,30+,31+,32+,33+,34+,35-,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47+,48-,49-,50+,51-,52-,53-,54-,55-,58+,59+,60+,62+,63+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Platycodin D3 exerts anti-Hepatitis C virus (HCV) activity. 2. Platycodin D3 could as expectorants in diverse inflammatory pulmonary diseases, it can regulate the production and secretion of airway mucin. 3. Platycodin D3 is a NF-κB inhibitor. 4. Platycodin D3 can significantly enhance mitogen- and OVA-induced splenocyte proliferation in the OVA-immunized mice. |
| Targets | HCV | IFN-γ | NF-kB |
Platycodin D3 Dilution Calculator
Platycodin D3 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.7207 mL | 3.6037 mL | 7.2074 mL | 14.4147 mL | 18.0184 mL |
| 5 mM | 0.1441 mL | 0.7207 mL | 1.4415 mL | 2.8829 mL | 3.6037 mL |
| 10 mM | 0.0721 mL | 0.3604 mL | 0.7207 mL | 1.4415 mL | 1.8018 mL |
| 50 mM | 0.0144 mL | 0.0721 mL | 0.1441 mL | 0.2883 mL | 0.3604 mL |
| 100 mM | 0.0072 mL | 0.036 mL | 0.0721 mL | 0.1441 mL | 0.1802 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lucidin 3-O-primeveroside
Catalog No.:BCN8584
CAS No.:29706-59-0
- Ligupurpuroside C
Catalog No.:BCN8583
CAS No.:1194056-33-1
- Isorosmanol
Catalog No.:BCN8582
CAS No.:93780-80-4
- Isoginsenoside Rh3
Catalog No.:BCN8581
CAS No.:166040-90-0
- Uvarigrin
Catalog No.:BCN8580
CAS No.:200563-11-7
- 4-Benzamido-2,5-diethoxybenzenediazonium
Catalog No.:BCN8579
CAS No.:5486-84-0
- Hexamethylquercetagetin
Catalog No.:BCN8578
CAS No.:1251-84-9
- Epitheaflagallin 3-O-gallate
Catalog No.:BCN8577
CAS No.:102067-92-5
- 5,6-Dehydroginsenoside Rd
Catalog No.:BCN8576
CAS No.:1268459-68-2
- Jionoside D
Catalog No.:BCN8575
CAS No.:120406-34-0
- Tectol
Catalog No.:BCN8574
CAS No.:24449-39-6
- Perisesaccharide B
Catalog No.:BCN8573
CAS No.:1095261-93-0
- Sarracenin
Catalog No.:BCN8586
CAS No.:59653-37-1
- Glyasperin C
Catalog No.:BCN8587
CAS No.:142474-53-1
- Rubiayannone A
Catalog No.:BCN8588
CAS No.:517978-25-1
- Hydroquinidine
Catalog No.:BCN8589
CAS No.:1435-55-8
- Aaptamine
Catalog No.:BCN8590
CAS No.:85547-22-4
- Firmanoic acid
Catalog No.:BCN8591
CAS No.:107584-83-8
- Licoflavone B
Catalog No.:BCN8592
CAS No.:91433-17-9
- Cinobufaginol
Catalog No.:BCN8593
CAS No.:6691-83-4
- Jasminoside B
Catalog No.:BCN8594
CAS No.:214125-04-9
- Ophiopogonoside A
Catalog No.:BCN8595
CAS No.:791849-22-4
- Dehydronuciferine
Catalog No.:BCN8596
CAS No.:7630-74-2
- Licoflavone A
Catalog No.:BCN8597
CAS No.:61153-77-3
Bioactivity-integrated ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry for the identification of nuclear factor-kappaB inhibitors and beta2 adrenergic receptor agonists in Chinese medicinal preparation Chuanbeipipa dropping pills.[Pubmed:23483566]
Biomed Chromatogr. 2013 Aug;27(8):960-7.
A simple and dual-target method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry combined with dual-bioactive [nuclear factor-kappaB (NF-kappaB) and beta2 -adrenergic receptor] luciferase reporter assay systems was developed to rapidly characterize the chemical structure of various bioactive compounds of TCM preparations. Chuanbeipipa dropping pills, a traditional Chinese medicine preparation used for the clinical therapy of chronic obstructive lung disease and cough caused by bronchial catarrh, was analyzed with this method. Potential anti-inflammatory and spasmolytic constituents were screened using NF-kappaB and beta2 -adrenergic receptor activity luciferase reporter assay systems and simultaneously identified according to the time-of-flight mass spectrometry data. One beta2-adrenergic receptor agonist (ephedrine) and two structural types of NF-kappaB inhibitors (platycosides derivatives and ursolic acid derivatives) were characterized. Platycodin D3 and E were considered new NF-kappaB inhibitors. Further cytokine and chemokine detection confirmed the anti-inflammatory effects of the potential NF-kappaB inhibitors. Compared with conventional fingerprints, activity-integrated fingerprints that contain both chemical and bioactive details offer a more comprehensive understanding of the chemical makeup of plant materials. This strategy clearly demonstrated that multiple bioactivity-integrated fingerprinting is a powerful tool for the improved screening and identification of potential multi-target lead compounds in complex herbal medicines.
Triterpenoid Saponins Isolated from Platycodon grandiflorum Inhibit Hepatitis C Virus Replication.[Pubmed:24489585]
Evid Based Complement Alternat Med. 2013;2013:560417.
Hepatitis C virus (HCV) infection is a major cause of liver disease, including cirrhosis and hepatocellular carcinoma. Due to significant adverse effects and emergence of resistant strains of currently developed anti-HCV agents, plant extracts have been considered to be potential sources of new bioactive compounds against HCV. The aim of this study was to evaluate the functional effects of triterpenoid saponins contained in the root extract of Platycodon grandiflorum (PG) on viral enzyme activities and replication in both HCV replicon cells and cell culture grown HCV- (HCVcc-) infected cells. Inhibitory activities of triterpenoid saponins from PG were verified by NS5B RNA-dependent RNA polymerase assay and were further confirmed in the context of HCV replication. Six triterpenoid saponins (platycodin D, platycodin D2, Platycodin D3, deapioplatycodin D, deapioplatycodin D2, and platyconic acid A), PG saponin mixture (PGSM), were identified as active components exerting anti-HCV activity. Importantly, PGSM exerted synergistic anti-HCV activity in combination with either interferon- alpha or NS5A inhibitors. We demonstrated that combinatorial treatment of PGSM and IFN- alpha efficiently suppressed colony formation with significant reduction in drug resistant variant of HCV. These data suggest that triterpenoid saponin may represent a novel anti-HCV therapeutic agent.
Effects of the root of Platycodon grandiflorum on airway mucin hypersecretion in vivo and platycodin D(3) and deapi-platycodin on production and secretion of airway mucin in vitro.[Pubmed:24290472]
Phytomedicine. 2014 Mar 15;21(4):529-33.
We investigated whether aqueous extract of the root of Platycodon grandiflorum A. de Candolle (APG), platycodinD(3) and deapi-platycodin significantly affect the production and secretion of airway mucin using in vivo and in vitro experimental models. Effect of APG was checked on hypersecretion of pulmonary mucin in sulfur dioxide-induced bronchitis in rats. Confluent NCI-H292 cells were pretreated with platycodinD(3) or deapi-platycodin for 30min and then stimulated with PMA (phorbol 12-myristate 13-acetate) for 24h. The MUC5AC mucin production and secretion were measured by ELISA. The results were as follows: (1) APG stimulated the secretion of airway mucin in sulfur dioxide-induced bronchitis rat model; (2) platycodinD(3) and deapi-platycodin inhibited the production of MUC5AC mucin induced by PMA from NCI-H292 cells, respectively; (3) however, platycodinD(3) and deapi-platycodin did not inhibit but stimulated the secretion of MUC5AC mucin induced by PMA from NCI-H292 cells, respectively. This result suggests that aqueous extract of P. grandiflorum A. de Candolle and the two natural products derived from it, platycodinD(3) and deapi-platycodin, can regulate the production and secretion of airway mucin and, at least in part, explains the traditional use of aqueous extract of P. grandiflorum A. de Candolle as expectorants in diverse inflammatory pulmonary diseases.
Platycodin D and D3 increase airway mucin release in vivo and in vitro in rats and hamsters.[Pubmed:11914958]
Planta Med. 2002 Mar;68(3):221-5.
The root of Platycodon grandiflorum has been widely used for the treatment of various chronic inflammatory diseases including airway disease in oriental medicine. The root extract of the plant has been known to be effective in the expectoration of sputum or mucus, thereby improving airway respiratory function and preventing secondary airway inflammation. In this study, we investigated the effect of platycodin D and D3, the saponin components that are anti-inflammatory components in Platycodon grandiflorum. Platycodin D and D3 increased mucin release from rat and hamster tracheal surface epithelial cell culture and also from intact rat trachea upon nebulization. The effect of Platycodin D3 was stronger than that of ATP, a potent mucin secretagogue and also of ambroxole, a mucolytic drug. The results from the present study suggest that platycodin D and D3 are useful as expectorant agents in the treatment of various airway diseases.
